bta takeover very possible, page-8

dday,

Just in case you are interested, here are the sales data:


In February when Roche & GSK reported the sales for the year (note the Roche & GSK 12 months sales end in December)
Tamiflu sales for the 12 months to December was CHF3.2 billion
The exchange rate at that time was 1CHF = US$ 0.94 = $US3.008 billion
GSK reported 12 months sales of Relenza at $1.123 billion Therefore Relenza market share was 27%

In the current 3 months sales,
Tamiflu sales is CHF517 million with 1CHF almost the same as 1 Australian $
Peter Cook reported Relenza sales at Australian $138 million = 21% market share

BTA told us GSK is very committed to selling Relenza, how come GSK lost market share from 27% to 21 to tamipoo?

Where is the rebalancing to 50/50?

Who is lying? The Sales Data? Biota clever management had a history of telling shareholders one thing while market data showed it differently.

Remember Clever Management refused GSK $100m settlement offer and after spending tens of millions of legal fees told shareholders how wonderful it was to accept a $20million settlement. The CEO even collected hundreds of thousands of free options for the clever settlement.

Please ask clever management why market share actually dropped.